-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Fourth Pharmaceutical has once again made it into the top 50 Chinese companies in terms of R&D strength in chemical pharmaceuticals.
Category:
Time：2021-09-23
On September 18, at the 2021 High-Quality Development Conference for the Greater Health Industry and the 6th China Pharmaceutical R&D & Innovation Summit (PDI) held in Chongqing, the Top 100 Ranking of China’s Chemical Drug R&D Strength for 2021 was released. Shijiazhuang Fourth Pharmaceutical Co., Ltd. ranked 44th, once again making it into the top 50 Chinese companies in chemical pharmaceutical R&D strength.
On September 18, at the 2021 High-Quality Development Conference for the Greater Health Industry and the 6th China Pharmaceutical R&D & Innovation Summit (PDI) held in Chongqing, the Top 100 Ranking of China’s Chemical Drug R&D Strength for 2021 was released. Shijiazhuang No.4 Pharmaceutical Co., Ltd. ranked 44th, once again making it into the top 50 Chinese companies in chemical pharmaceutical R&D strength.
R&D investment is one of the key indicators of innovative capability. According to data from Frost & Sullivan, R&D spending by innovative pharmaceutical companies has continued to grow over the past five years. From 2016 to 2020, China’s total R&D expenditure in the pharmaceutical sector increased from US$11.9 billion to US$27 billion, with a compound annual growth rate of 22.7%. Among the companies listed, 24 had R&D expenditures exceeding 500 million yuan in 2020, and 8 had R&D investments surpassing 1 billion yuan.
With the implementation of policies such as “Generic Drug Consistency Evaluation,” “Volume-Based Procurement,” “Medical Insurance Negotiations,” and the “MAH System,” the market structure of the pharmaceutical industry is undergoing continuous adjustment and differentiation. The competitive landscape has shifted from being centered on manufacturing to being centered on R&D capabilities and drug innovation. Innovative enterprises that prioritize R&D will usher in unprecedented development opportunities.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license